Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Secondary Malignant Neoplasm of Liver
and you are
between 18 and 80
years old
The phase for this study is not defined.
Show me locations

The purpose

The surgical and local ablation strategy for the treatment of resectable synchronous and metachronous colorectal liver metastases(CRLM) has not still been defined. The purpose of this study is to compare two treatment strategies in which simultaneous resection of both primary and secondary tumor of synchronous CRLM(SCRLM) and resection of metachronous CRLM(MCRLM) is compared with resection of primary tumor and ablation of secondary tumor in SCRLM and ablation of MCRLM. Endpoints include the rate of severe complications and survival.

Provided treatments

  • Procedure: CRLM resection group
  • Device: CRLM ablation group
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02886104. The sponsor of the trial is Sixth Affiliated Hospital, Sun Yat-sen University and it is looking for 548 volunteers for the current phase.
Official trial title:
Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis (HELARC) ------ a Randomized Controlled Multicenter Clinical Study